Journal of Cardiac Failure最新文献

{"title":"Comparison of Heart Failure Cardiogenic Shock Patients with Axillary and Femoral Intra-aortic Balloon Pump: Cardiogenic Shock Working Group report.","authors":"Arvind Bhimaraj, Arthur R Garan, Qiuyue Kong, J U Kim, Mohit Pahuja, Ajar Kochar, Smitha Narayangowda, Borui Li, Song Li, Shashank S Sinha, Gavin W Hickey, Rachna Kataria, VAN-Khue Ton, Scott Lundgren, Sandeep Nathan, Esther Vorovich, Shelley Hall, Wissam Khalife, Andrew Schwartzman, Oleg Alec Vishnevsky, Elric Zweck, Justin Fried, Mary Jane Farr, Claudius Mahr, Joseph Mishkin, I-Hui Chiang, Onyedika Ilonze, Alexandra Arias, Jeffrey Marbach, Hiram Bezerra, Paavni Sangal, Karol D Walec, Peter Zazzali, Neil M Harwani, Vanessa Blumer, Kevin John, Jaime Hernandez-Montfort, Jacob Abraham, Daniel Burkhoff, Manreet K Kanwar, Navin K Kapur","doi":"10.1016/j.cardfail.2025.07.020","DOIUrl":"10.1016/j.cardfail.2025.07.020","url":null,"abstract":"<p><strong>Background: </strong>IABPs traditionally are placed via the femoral artery. Single-center studies have shown the utility of axillary placement to promote ambulation. The utility of Ax IABP in CS has not been established. Therefore, we sought to describe the outcomes of patients receiving axillary (Ax) intra-aortic balloon pump (IABP) and compare them with those receiving femoral (Fem) IABP for heart failure-related cardiogenic shock (HF-CS).</p><p><strong>Methods: </strong>Data from 2020 to 2023 from the Cardiogenic Shock Working Group, a multicenter academic consortium, were analyzed. We examined the demographic, metabolic, hemodynamic characteristics, and outcomes of patients with HF-CS treated with Ax-IABP and compared them with those who primarily received a Fem-IABP.</p><p><strong>Results: </strong>Of 6201 CS patients in the registry, 557 (8.9%) patients received an IABP for HF-CS, of whom 244 (43.8%) and 313 (56.2%) received Ax-IABP and Fem-IABP, respectively. Compared with Fem-IABP, patients who received Ax-IABP were more likely to have previous intracardiac defibrillators (42.5% vs 68.9%, P < .001). Time to IABP implant from admission (7.9 ± 10.6 vs 1.8 ± 6.1, P < .01) and duration of support (9.6 ± 14.6 vs 4.0 ± 4.5, P < .01) were longer among Ax-IABP, relative to Fem-IABP. Patients who received Ax-IABP were more likely to undergo heart-replacement therapy (65% vs 21%, P < .001) compared with the Fem-IABP cohort. The rate of reported complications was similar between the 2 groups.</p><p><strong>Conclusion: </strong>Axillary IABP is being used beyond single-center reports to support HF-CS mostly as a bridge to heart-replacement therapies. Its use might provide advantages over fem-IABP.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotypes of Peril: The Hidden Burden of End-Organ Failure in Cardiogenic Shock.","authors":"Nitish K Dhingra, Moritz Blum, Mandeep R Mehra","doi":"10.1016/j.cardfail.2025.08.004","DOIUrl":"10.1016/j.cardfail.2025.08.004","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To ICD or not to ICD: Is That the Question?","authors":"Sojin Y Wass, Amanda R Vest, Pasquale Santangeli","doi":"10.1016/j.cardfail.2025.07.022","DOIUrl":"10.1016/j.cardfail.2025.07.022","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements and Challenges in Acute Heart Failure Management in Korea: Initial Report and Insights from the Korean Heart Failure III Registry.","authors":"Huijin Lee, Eung Ju Kim, Seong Woo Han, Seong-Mi Park, Hyung-Seop Kim, Myung-Chan Cho, Hyo-Suk Ahn, Mi-Seung Shin, Seok-Jae Hwang, Jin-Ok Jeong, Dong Heon Yang, Junho Hyun, Jin Oh Choi, Hae-Young Lee, Byung-Su Yoo, Seok-Min Kang, Dong-Ju Choi, Hyun-Jai Cho","doi":"10.1016/j.cardfail.2025.07.023","DOIUrl":"10.1016/j.cardfail.2025.07.023","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) is a major global health burden. Building on 2 previous national registries, the Korean Heart Failure III (KorHF III) registry provides a contemporary evaluation of clinical characteristics, treatment patterns, and outcomes in patients hospitalized with acute HF (AHF) in Korea.</p><p><strong>Methods and results: </strong>KorHF III prospectively enrolled 7351 patients with AHF from 47 tertiary hospitals between March 2018 and December 2022, with a 2-year follow-up. HF with reduced ejection fraction accounted for 57.3% of all cases. Common comorbidities included hypertension (59.5%) and diabetes (40.0%). The most frequent etiologies were ischemic heart disease (27.7%) and dilated cardiomyopathy (24.9%). At discharge, 74.3% of patients received angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin inhibitors; 68.5% received beta-blockers; and 57.4% received mineralocorticoid receptor antagonists. Prescriptions of sodium-glucose cotransporter 2 inhibitor were 15.8%. In-hospital mortality was 2.2%, and 2-year mortality was 20.9%, greatest among patients with HF with preserved ejection fraction (24.6%). Hyponatremia was independently associated with in-hospital (hazard ratio 2.50, P < .001) and postdischarge mortality (HR 1.72, P < .001).</p><p><strong>Conclusions: </strong>KorHF III provides the most comprehensive and current assessment of AHF in Korea. Despite high prescription rates of guideline-directed medical therapy and low in-hospital mortality, long-term mortality is substantial. These findings emphasize the need for improved postdischarge care and highlight hyponatremia as a key prognostic factor in AHF management.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Equity in Heart Failure Follow-Up: Aligning Resource Allocation with Risk.","authors":"Maggie Simpson, Avery C Bechthold, Kathleen L Grady","doi":"10.1016/j.cardfail.2025.07.018","DOIUrl":"10.1016/j.cardfail.2025.07.018","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing real-world use of vericiguat in the United States.","authors":"Alejandro Victores, Lori D Bash, Boshu Ru, Arielle Marks-Anglin, Ciaran McMULLAN, Andra Stevenson, Engels N Obi, Robert J Mentz, James L Januzzi","doi":"10.1016/j.cardfail.2025.07.021","DOIUrl":"10.1016/j.cardfail.2025.07.021","url":null,"abstract":"<p><strong>Background: </strong>Contemporary data regarding uptake of vericiguat for treatment of heart failure (HF), including achievement of target dose (10 mg), are lacking.</p><p><strong>Methods: </strong>A retrospective analysis of TriNetX claims data was conducted. The study included US adults with HF receiving vericiguat from January 20, 2021, to November 20, 2023. Baseline patient characteristics, health care resource use, and follow-up vericiguat titration were described. Multivariable logistic regression models identified factors associated with reaching the vericiguat target dose.</p><p><strong>Results: </strong>The study sample included 5149 patients (mean age 68 years, 67% male, 55% White). Common comorbidities included hypertension (89%) and hyperlipidemia (81%). Over a 12-month baseline, 35%, 44%, and 38% of patients experienced worsening HF events, all-cause hospitalizations, and emergency department visits, respectively. Common guideline-directed medical therapy (GDMT) classes received at baseline included beta-blockers (74%), angiotensin receptor neprilysin inhibitors (ARNi; 52%), sodium glucose cotransporter-2 inhibitors (SGLT2i; 44%), and mineralocorticoid receptor antagonists (MRAs; 40%). Approximately 36% of patients reached the vericiguat target dose over a median (interquartile range) follow-up of 433 (247-606) days. Factors associated with reaching the target dose included age, baseline medication with MRAs, beta-blockers, or combination therapy with ARNi and SGLT2i, and the Charlson Comorbidity Index score.</p><p><strong>Conclusion: </strong>Approximately one-third of patients treated with vericiguat reached the 10-mg target dose during follow-up, with receipt of a beta blocker, MRA, or ARNi + SGLT2i combination at baseline associated with achievement of the target dose. These data inform contemporary use of novel GDMT and may support quality improvement efforts to enhance the effective implementation of GDMT in appropriate patients.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth Differentiation Factor-15 and the Effect of Dapagliflozin in Heart Failure: Insights From the DAPA-HF Trial.","authors":"David D Berg, Kieran F Docherty, Atefeh Talebi, Naveed Sattar, Petr Jarolim, Paul Welsh, Pardeep S Jhund, Inderjit S Anand, Rudolf A DE Boer, Eri T Kato, Lars Kober, Felipe A Martinez, Eileen O'Meara, Piotr Ponikowski, Morten Schou, Scott D Solomon, Ann Hammarstedt, John J V McMurray, Marc S Sabatine, David A Morrow","doi":"10.1016/j.cardfail.2025.07.019","DOIUrl":"10.1016/j.cardfail.2025.07.019","url":null,"abstract":"<p><strong>Background: </strong>Growth differentiation factor (GDF)-15, a stress-induced cytokine implicated in systemic energy homeostasis, is associated with adverse outcomes in heart failure (HF). This study evaluated the associations between baseline GDF-15 and the clinical characteristics and outcomes in patients with HF with reduced ejection fraction in the DAPA-HF (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure) trial. The effect of the sodium-glucose cotransporter-2 inhibitor dapagliflozin on circulating GDF-15 levels and the effect of dapagliflozin on clinical outcomes in relation to baseline GDF-15 concentrations were also examined.</p><p><strong>Methods and results: </strong>DAPA-HF was a randomized trial of dapagliflozin in patients with HF and LVEF ≤ 40%. GDF-15 was measured at baseline and 12 months. The primary outcome was the composite of worsening HF or cardiovascular death. The median baseline GDF-15 level was 1888 (IQR: 1323-2755) pg/mL. Higher GDF-15 levels were associated with older age, lower body mass index, and greater HF symptom burden. There was a stepwise increase in adjusted risk for the primary outcome across quartiles of baseline GDF-15 (adjusted hazard ratio [Q4 vs Q1] 2.30, 95% CI 1.66-18; P trend < 0.001). Dapagliflozin did not significantly change GDF-15 concentrations over 12 months, compared to placebo (placebo-corrected relative change +4%; 95% CI, -2% to +10%). The relative effect of dapagliflozin on the primary outcome was consistent across GDF-15 quartiles (P interaction = 0.96), with a greater absolute benefit in those with higher GDF-15 (P trend < 0.01).</p><p><strong>Conclusions: </strong>In DAPA-HF, GDF-15 was independently prognostic of worsening HF or cardiovascular death. Absolute risk reduction with dapagliflozin was greater in patients with higher baseline GDF-15, but the benefit was not associated with an effect on GDF-15 itself.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale, design, and baseline characteristics of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 left ventricular assist device recipients (ENVAD-HF).","authors":"Maja Cikes, Ivo Planinc, Jasper J Brugts, Brian Claggett, Ulrich P Jorde, Davor Milicic, Frank Ruschitzka, Nir Uriel, Nina Jakus, Filip Loncaric, Filip Puskaric, Pawel Rubis, Linda W van Laake, Igor Rudez, Marketa Hegarova, Mandeep Mehra, Scott D Solomon","doi":"10.1016/j.cardfail.2025.07.015","DOIUrl":"10.1016/j.cardfail.2025.07.015","url":null,"abstract":"<p><strong>Background: </strong>With notable improvements in long-term survival and hemocompatibility-related events, heart failure (HF) is emerging as a leading cause of death in the contemporary left ventricular assist device (LVAD) population. Although prospective randomized controlled trials have not investigated the use of HF therapies in recipients of LVAD, observational data suggest benefits of neurohormonal blockers, especially in achieving blood pressure (BP) targets associated with improved outcomes.</p><p><strong>Methods: </strong>The study \"multicENter, randomized, open-label, parallel group, pilot study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients\" (ENVAD-HF) is an investigator-initiated prospective multicenter, randomized, open-label, parallel group, pilot study of recipients of HeartMate 3 (HM3) LVADs to evaluate the safety and tolerability and insights on efficacy of sacubitril/valsartan compared to standard of care (SOC) for managing BP. Medically stable recipients of LVADs after a recent HM3 implantation or in ambulatory follow-up were eligible for participation and randomized 1:1 to receive sacubitril/valsartan or SOC used for treating BP, both titrated aiming for a mean arterial pressure goal 75-90 mm Hg over a 12-month follow-up. The primary endpoint, designed to assess the safety and efficacy of sacubitril/valsartan compared with SOC, is a composite of freedom from all-cause death, deterioration in renal function, hyperkalemia, or symptomatic hypotension. The occurrence of the primary endpoint will be assessed in the first three months and during the overall duration of the trial (12 months). Other endpoints include clinical and patient-reported outcomes, biomarker, and echocardiography assessments during follow-up.</p><p><strong>Results: </strong>ENVAD-HF enrolled 60 patients between February 2021 and March 2024: 17% were female, mean age was 57 ± 12 years, 67% were in ambulatory follow-up, 55% had ischemic etiology, and 25% were receiving an LVAD as destination therapy, with mean baseline mean arterial pressure 87 ± 7 mm Hg and median N-terminal pro B-type natriuretic peptide 2552 (1595-3543) pg/mL.</p><p><strong>Conclusion: </strong>ENVAD-HF is the first prospective randomized controlled trial of pharmacologic therapy for the management of BP in stable recipients with HM3 LVADs achieving target enrollment. It will provide data on safety, tolerability, and insights on efficacy of sacubitril/valsartan versus SOC used for treating BP.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144862265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is it Time to invest in Systematic and Early Myocardial Biopsies for Nonischemic Cardiomyopathy? Reporting our Electroanatomic Voltage Mapping-Guided Endomyocardial Biopsy Experience.","authors":"Farhan Ishaq, Miguel Valderrabano, Arvind Bhimaraj","doi":"10.1016/j.cardfail.2025.07.014","DOIUrl":"10.1016/j.cardfail.2025.07.014","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Continuum of Prevention and Heart Failure in Cardiovascular Medicine: A Joint Scientific Statement from the Heart Failure Society of America and The American Society for Preventive Cardiology.","authors":"Anuradha Lala, Craig Beavers, Vanessa Blumer, Laprincess Brewer, Diana De Oliveira-Gomes, Sandra B Dunbar, Hannah Every, Richard Ferraro, Bonnie Ky, James L Januzzi, Francoise Marvel, Robert J Mentz, Erin Michos, Jagat Narula, Khuram Nasir, Pradeep Natarajan, Lori Ann Peterson, Fatima Rodriguez, Michael D Shapiro, Jenna Skowronski, Randall C Starling, Pam Taub, Ryan J Tedford, Quentin Youmans, Shelley Zieroth, Martha Gulati","doi":"10.1016/j.cardfail.2025.06.013","DOIUrl":"10.1016/j.cardfail.2025.06.013","url":null,"abstract":"<p><p>Heart disease is the leading cause of death worldwide, with heart failure (HF) recognized as its most severe and debilitating manifestation. Though remarkable advancements have led to the establishment of life-saving and quality-of-life-enhancing medical and device-based therapies for HF, HF-related mortality trends have increased over the past decade. To combat this worldwide epidemic, care must evolve so that preventive recommendations are not siloed from HF management. Prevention must be prioritized more broadly, not only in the early detection and deterrence of HF but across a patient's lifespan in conjunction with therapeutic intervention. Members of the Heart Failure Society of America and the American Society for Preventive Cardiology created this joint Societal Scientific Statement on the Prevention of Heart Failure to emphasize the links between cardiovascular disease prevention and HF and offer a conceptual roadmap along which to consider all aspects of preventive care. This includes primary prevention to reduce the burden of HF, secondary prevention to reduce the impact of HF among those with an established diagnosis of HF, and tertiary prevention, which encompasses the management of risk factors in patients who require advanced therapies, including durable mechanical circulatory support and heart transplantation.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}